# Corporate Profile





For a Healthy Tomorrow and Future.







Holdings

ASKA
Pharmaceutical Holdings Co., Ltd.

Corporate Message

# For a Healthy Tomorrow and Future.

Dedicated to all of those wishing to live their lives to the fullest, at their own command.
Toward a society in which people and animals would happily co-exist.
As a company with a century-long history of drug discovery,
we value the importance of continuously delivering new hopes to all of us.
As a pioneer in hormone preparations and a leading company
in women's healthcare, we aspire to become a "total healthcare company"
with a comprehensive approach integrating disease prevention,
testing and diagnostics, treatment, and prognosis.
We do remain fully committed to taking on the challenge of
creating a healthy tomorrow and future for all of us.

Corporate Philosophy

**Contribute toward the improvement of people's health and progress in society through the development of innovative products**

## To further enhance corporate value, we will continue to create new value and pursue further development and growth.

While cherishing the strengths we have cultivated over the years,
we aspire to remain a company that continues to create new value for society,
not only ten years from now, but well into the future.
We have embodied this aspiration in a single direction:
"ASKA VISION 2035."
As the environment surrounding society and healthcare undergoes profound change,
we have chosen to transform ourselves.
And now, we are steadily taking action toward realizing this vision.
We sincerely ask for your continued understanding
and support of ASKA Pharmaceutical Holdings Co., Ltd.
as we continue to take on new challenges.

President, Representative Director
Sohta Yamaguchi



## ASKA Pharmaceutical

### As a pioneer in hormone pharmaceuticals, we contribute to improving people's health and quality of life

ASKA Pharmaceutical Co., Ltd. is a specialty pharma company focused on hormone pharmaceuticals, developing a prescription pharmaceutical business specializing in three therapeutic areas: (Ob/Gyn), internal medicine (gastroenterology and thyroid diseases), and urology. Building on the expertise and knowledge we have cultivated as a pioneer in hormone pharmaceuticals, we have established a leading position in the field of obstetrics and gynecology and earned a high level of trust among healthcare professionals. In addition, leveraging our research and development capabilities cultivated over many years, we are actively pursuing the development of new drugs and overseas expansion, expanding our business in growing markets, particularly in Southeast Asia. With a focus on products that support women throughout the various stages of their lives, we aim to address unmet medical needs and achieve sustainable growth while contributing to society. Going forward, we will continue to leverage our high level of expertise and contribute to improving people's health and quality of life through the stable supply of high-quality pharmaceuticals and the appropriate collection and provision of medical information.

- Obstetrics and Gynecology
- Internal Medicine (Gastroenterology and Thyroid Diseases)
- Urology

## ASKA Animal Health

### Contributing to a society where people and animals can coexist

ASKA Animal Health Co., Ltd. contributes to livestock farmers and veterinary healthcare professionals through the research and development, manufacturing, import, and sale of veterinary pharmaceuticals and other products that help maintain and improve the productivity of livestock and fisheries, which form the foundation of Japan's food self-sufficiency, as well as maintain the health of companion animals such as dogs and cats.
In particular, in the livestock and fisheries sectors, we focus on our core strengths of "reproduction, immunity, and nutrition." Through the use of key products such as reproductive hormones and amino acids, we strive to contribute to improving the productivity of livestock and fisheries.
Food safety is the greatest need of consumers. By making continuous efforts to ensure that consumers can enjoy food with confidence, we will continue to pursue our corporate philosophy of contributing to the creation of a society in which people and animals can coexist.

- Companion Animal Business
- Livestock and Fisheries Business

Holdings

# ASKA Pharmaceutical Holdings Co., Ltd.

Leveraging the synergies of our holding company structure for the further development and growth of the ASKA Group as a whole

## ASKA Pharma Medical

### Contributing to a healthier society through advanced measurement technologies

ASKA Pharma Medical Co., Ltd. leverages the advanced technologies and extensive expertise it has cultivated over the years to contribute to a wide range of fields, including basic research, clinical research, and diagnostics, with a focus on the measurement of biologically active substances, including steroid hormones, as part of its testing business.
In particular, using our proprietary, highly accurate and highly sensitive measurement technologies based on liquid chromatography-tandem mass spectrometry (LC-MS/MS), we provide contract testing services to meet a wide range of measurement needs for various types of specimens.
By developing measurement technologies using non-invasive, self-collectable specimens such as hair and saliva, we aim to lower the barriers to undergoing testing and contribute to increasing testing rates by making hormone status more visible.
As interest in preventive healthcare and measures to address the pre-disease state continues to grow, we will leverage these advanced technologies to meet the growing demand for highly accurate testing across a broader range of fields, thereby contributing to the realization of a healthier society and enhancing corporate value.

- Trace Measurement of Endogenous Hormones
- Measurement Using Non-Invasive Specimens (Hair, Saliva, etc.)

## Ha Tay Pharmaceutical Joint Stock Company

### Achieving sustainable growth and contributing to the health and well-being of people in Vietnam

Ha Tay Pharmaceutical Joint Stock Company (Hataphar) is one of Vietnam's leading pharmaceutical companies, with a history spanning more than 60 years and a listing on the Hanoi Stock Exchange. As a pharmaceutical manufacturer with an integrated business structure covering research and development, manufacturing, sales, and distribution, the company provides a wide range of products, primarily prescription pharmaceuticals as well as health supplements, contributing to the maintenance and improvement of the health of people in Vietnam.
The company has also established production facilities and quality management systems that comply with international standards, enabling the stable supply of high-quality pharmaceuticals. While meeting diverse healthcare needs in Vietnam, Hataphar has also been actively expanding its business overseas in recent years, with the aim of further developing as a manufacturing base responsible for supplying pharmaceuticals throughout Asia in the future. Going forward, the company will continue to strengthen its business foundation and pursue sustainable growth through the provision of reliable products and services, with the goal of becoming a "healthcare company trusted and chosen by customers."

- Prescription Pharmaceuticals
- Over-the-Counter (OTC) Pharmaceuticals

# History of Value Creation

Since our founding in 1920 as a pioneer in hormone preparations, we have unerringly continued on our journey, while always keeping in mind our essential mission as a company that is directly linked to life and health. In 2021, we transitioned to a holding company structure, and took a new step toward the next 100 years. We will continue to respond to the changing times and environment, and contribute to society as we evolve into a total healthcare company.

## 1920–1955
### Took our first step as a pharmaceutical company

In 1920, Yasohachi Yamaguchi established Teikoku Hormone Research Institute. It began the research, development, manufacture and sales of hormone preparations based on the unique idea of creating useful medicines from animal organs. Although the company experienced hardships such as the Great Kanto Earthquake, and the loss of its head office and factory during the Second World War, it was rebuilt under a new organizational structure, and listed its shares on the Tokyo Stock Exchange in 1955.

Launched in 1921
Male gonadal hormone agent
SPERMATIN



Launched in 1922
Hypothyroidism agent
THYRADIN




Launched in 1926
Posterior pituitary hormone agent
ATONIN




## 1955 – 2005
### Became a company that makes wide-ranging contributions to society

After the postwar reconstruction period, the company worked to modernize its management through organizational reforms, expansion of its sales and production systems, reorganization of its research functions, and reinforcement of its advertising activities. In addition to entering the field of veterinary pharmaceuticals, the company also strived to diversify its business and work toward corporate growth in the midst of an era of rapid economic growth.

Launched in 1981
Benign prostatic hyperplasia and prostate cancer agent
PROSTAL



Launched in 1986
Gastritis and gastric ulcer agent
ALTAT




Launched in 1999
Low-dose oral contraceptive
ANGE



**1945**
**Women's suffrage in Japan**

**1975**
**International Women's Year**

## Financial Performance
(Millions of yen)



## 2021 –

### Aim for further growth

ASKA Pharmaceutical Holdings' Medium-Term Management Plan 2025 was launched in 2021. In conjunction with the shift to a holding company structure, the Company not only aims to build a flexible organization that is capable of swift decision-making, but also to achieve further sustainable growth for the entire Group by further strengthening its governance structure.

## 2005 – 2021

### Formation of ASKA Pharmaceutical Co., Ltd.

In 2005, ASKA Pharmaceutical Co., Ltd. was established to develop and market new drugs, specializing in the three priority areas of internal medicine, obstetrics and gynecology (Ob/Gyn), and urology with the aim of becoming a competitive specialty pharma company. The company took on challenges for the next stage, such as strengthening efforts for generic drugs that meet the needs of the times.

Launched in 2011
Hyperlipidemic agent
LIPIDIL



Launched in 2014
Antihypertensive agent
CANDESARTAN "ASKA"



Launched in 2016
Hepatic encephalopathy agent
RIFXIMA



Launched in 2021
Hair hormone level measurement kit
Dihydrotestosterone



Launched in 2014
Endometriosis, uterine fibroids, and prostate cancer agent
LEUPRORELIN "ASKA"



Launched in 2016
Infertility agent
LUTEUM



Launched in 2019
Uterine fibroids and endometriosis agent
RELUMINA



Launched in 2021
Feline hyperthyroidism agent
THYLOBLOCK



**2022**
**Enforcement of Revised Act on the Promotion of Women's Participation and Advancement in the Workplace**

FY2025
¥71,127million

45,849

**2016**
**Enforcement of Act on the Promotion of Women's Participation and Advancement in the Workplace**

23,537

**1986**
**Act on Securing, Etc. of Equal Opportunity and Treatment between Men and Women in Employment**

24,390

12,409

**1992**
**Enforcement of Childcare Leave Act***

1,043

5,020

2,659

3,496

5,834

Launched in 2022
Canine hyperadrenocorticism agent
TRILOSTANE TABLET "ASKA"



Launched in 2022
Dysmenorrhea agent
DroEthi "ASKA"



Launched in 2025
Oral contraceptive
Slinda



Launched in 2023
Hair and nail stress hormone level test kit
Cortisol



Launched in 2023
Hair Hormone level measurement kit
"Testosterone"



Launched in 2024
Hair Hormone level measurement kit
"Proges"



*Currently Act on Childcare Leave, Caregiver Leave, and Other Measures for the Welfare of Workers Caring for Children or Other Family Members

1980 1990 2000 2010 2020

Net sales

Operating profit

Six-month settlement period

Consolidated accounting
(Merged with Grelan Pharmaceutical Co., Ltd. in October 2005)

# Value Creation Process

ASKA Pharmaceutical Holdings aims to become a total healthcare company with a strong foundation as a specialty pharma company through its pharmaceutical business, animal health business, and hormone testing business, based on ASKA's DNA, the source of its growth for over 100 years. Through this value creation cycle, we will contribute to the resolution of social issues in the field of healthcare.

## INPUT

**Human Capital**
High level of expertise and diversity

**Financial Capital**
Financial foundation and aggressive investment

**Intellectual Capital**
Accumulated know-how

**Manufactured Capital**
Quality culture

**Social Capital**
Strong customer base

**Natural Capital**
Sustainable social contribution

## BUSINESS MODEL

**Core Competencies**

Highly specialized human resources and organizational strength

Unwavering trust from stakeholders

Strong presence in specialty areas

- Global
- Drug Discovery
- Domestic Pharmaceutical
- Testing and Around-the-Pill
- Animal Health

### Two Foundations

**Financial Strategy**
Advanced management with a focus on the cost of capital

**Strengthening the Management Foundation**
Strengthening the management infrastructure to execute strategies

**6 Material Issues**

①Promotion of environmental management
②Developing diverse human resources to enhance corporate value
③Contributing to women's health and animal health
④Stable supply of high-quality products and provision of appropriate information
⑤Respect for human rights ⑥Strengthening governance







## OUTPUT/OUTCOME

Addressing Unmet Needs in Drug Discovery for

**Patients and Healthcare Providers**

**Shareholders and Investors**

Enhancing corporate value and ensuring transparency

**Employees**

Growth opportunities and job satisfaction

**Value We Deliver**

Stakeholder Value Creation

**Business Partners**

Strengthening the foundation of trust and creating value through co-creation

**Local Communities**

Contributions to people and animals, sustainable businesses

**Politics and Administration**

Promotion of health policies and promotion of disease awareness

**ASKA VISION 2035**

**Toward a Specialty Healthcare Company Based in Japan, Pioneering the Future Globally**

**Economic Value**

**Mid-Term Management Plan 2028 (Consolidated target)**

Net sales: 85.0 billion yen
Operating Profit Margin: 10%
ROE: 10%

**Mid-Term Management Plan 2031**



ASKA Pharmaceutical Holdings Long-Term Vision

# ASKA VISION 2035

## Toward a Specialty Healthcare Company Based in Japan, Pioneering the Future Globally

As a specialty healthcare company leveraging our deep expertise to pioneer the future,
we are advancing the development of pharmaceuticals that transcend conventional approaches,
with the aim of delivering comprehensive healthcare spanning prevention, testing, diagnosis, treatment, and prognosis management.

**Mid-Term Management Plan 2028** (FY2026-2028)
Net Sales ¥85.0 billion
Operating Profit Margin 10%
Deepening core strengths for sustainable growth and building a business foundation to support global expansion

**Mid-Term Management Plan 2031** (FY2029-2031)
Net Sales ¥100.0 billion
Operating Profit Margin 12%
Expanding into new disease areas and establishing a foundation for global expansion

**Mid-Term Management Plan 2035** (FY2032-2035)
Net Sales ¥150.0 billion
Operating Profit Margin 15%
Establishing a strong presence in global markets through the integration of in-house developed products and group synergies

## Women's Healthcare × Growth Market

### Building on Our Strengths in the Hormone Field, Toward the Next Stage




ASKA Pharmaceutical Holdings Co., Ltd.

5-1, Shibaura 2-Chome, Minato-ku, Tokyo
108-8532, Japan
Tel: +81-3-5484-8845
https://www.aska-pharma-hd.co.jp/english/


Published in June 2026